Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial.

Caifeng LiXuemei TangZhixuan ZhouLi SunMeiping LuWei ZhouSirui YangWenjie ZhengHaiguo YuWeiping TanJunmei ZhangYu ZhangYuxiu KongJiahui Xu

Published in: Clinical rheumatology (2024)

This is the first multicentre trial to report the efficacy and safety of TCZ in Chinese patients with sJIA at 52 weeks. No new safety concerns were found.

Keyphrases

juvenile idiopathic arthritis
study protocol
clinical trial
phase iii
phase ii
randomized controlled trial
disease activity
double blind
rheumatoid arthritis
open label
cross sectional
systemic lupus erythematosus
placebo controlled
gestational age
drug induced
preterm birth